chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This case was reported by a physician via out of hour services and described the occurrence of nausea in a 12-year-old female patient who received Menveo (batch number M17058, expiry date 30th April 2019) for prophylaxis. On 6th August 2018, the patient received the 1st dose of Menveo (intramuscular). On 6th August 2018, 2 hrs after receiving Menveo, the patient experienced nausea. In August 2018, the patient experienced vomiting. On an unknown date, the outcome of the nausea and vomiting were unknown. It was unknown if the reporter considered the nausea and vomiting to be related to Menveo. Additional details were provided as follows: The patient after receiving vaccination remained in the office for 15 minutes and when she left was fine. The patient developed nausea on the way home and had been vomiting once an hour since the visit. There was no location reaction at the site and no fever.
102 degree fever that lasted 2-3 days; bright red, swollen left shoulder to half way down arm from site of injection; headache; chills' dizziness; blurry vision.
Lightheaded, pale and weak. Brought pt back to room layed him down. Once he could sit up  gave him juice. Mom was able to take him home.
Swelling in upper left arm x2d. This 5 year 4 month old male presents with 3 days of upper respiratory symptoms. Swelling in upper left arm x 2 days. Left deltoid measurement is 9 3/4 inch.
4 days after the vaccines began having multiple transient ischemic attacks, and episodes of syncope. Admitted to the hospital 10 days after vaccine with internal bleeding in her lungs, lungs full of blood clots and covid pneumonia. She required 2 blood transfusions because her hemoglobin was so low. She has been placed on hospice.
This spontaneous report as received from a Registered Nurse refers to a female patient of unknown age. On an unknown date the patient was vaccinated with VARIVAX (Merck) (lot # and expiration date unspecified) injection, 0.5 ml, subcutaneous. The Registered Nurse reported that the patient had received two doses of VARIVAX (Merck) on unspecified dates, however the patient's varicella titer was 0.9 after having received the required doses of VARIVAX (Merck). Patient did not seek medical attention, treatment was not given. At the time of the report the patient's outcome was unknown. Additional information has been requested.
achy all over; bad headache; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (achy all over) and HEADACHE (bad headache) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination.     No medical history was provided by the reporter .  Concomitant products included PARACETAMOL (TYLENOL) and IBUPROFEN for an unknown indication.    On 02-Sep-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Sep-2021, the patient experienced MYALGIA (achy all over) and HEADACHE (bad headache). At the time of the report, MYALGIA (achy all over) and HEADACHE (bad headache) outcome was unknown.            Treatment information was not provided
Information has been received on 13-DEC-2018 regarding a case in litigation from a lawyer concerning a female patient of unknown age. There was no information provided regarding the patient's concurrent conditions, medical history or concomitant medications. The patient's healthcare provider, recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. In 2009, a pharmacist at a pharmacy administered the ZOSTAVAX (lot number, expiration, dose and route unknown) to the patient. In 2015, the patient was treated by a healthcare provider at a hospital for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX, and suffered serious physical, emotional and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events is not recovered. The causality of the events is related. Additional information has been requested.
Presented to ER for SOB, tested positive (outside our system) 7 or 8 days prior to admission. Received Paxlovid and completed treatment on 11/20/22. Also tested positive for RSV.
Pt recvd a dose of Hep B vax (brand unk) in the buttock & it was determined that pt failed to seroconvert; No tx given;
Significant swelling (patient described as egg-shaped) with redness, itching, burning, and hot to the touch.  Patient went to her primary care physician who recommended diphenhydramine oral until symptoms subsided.
Dry cough; Lot of phlegm; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of COUGH (Dry cough) and PRODUCTIVE COUGH (Lot of phlegm) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Mar-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COUGH (Dry cough) and PRODUCTIVE COUGH (Lot of phlegm). At the time of the report, COUGH (Dry cough) and PRODUCTIVE COUGH (Lot of phlegm) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       no treatment information was provided  no concomitant medication were reported   Most recent FOLLOW-UP information incorporated above includes: On 25-May-2021: Follow up received on 25th MAY 2021 contains no new information
Red indurated upper (R) thigh. 5 in x 5 in. ? Varicella, ? DTaP.
Client came in for primary dose of Covid Vaccine series. Nurse accidentally administered a booster dose instead. Patient was immediately contacted when mistake was realized and asked to return to office for the correct primary dose. No adverse symptoms or reactions were reported by the client.
This spontaneous report was received from a healthcare worker, via company representative, regarding a female patient of unknown age. The patient's medical history, concurrent conditions, or concomitant therapies were not reported. On an unspecified date, the patient was vaccinated with a dose of an unidentified Merck HPV vaccine (name, strength, dose, lot number and expiration date were not provided) for prophylaxis. On an unknown date (reported as "after receipt of the vaccine"), the patient experienced warts that appeared on different parts of her body and had a long duration (unspecified). The patient received treatment for the event. The outcome of the event was unknown at the reporting time. The reporter did not provide a causality assessment between the event and the suspect vaccine. This is one of two reports of the same reporter. Additional information is not expected as the reporter refused additional contact. Sender's Comments: US-009507513-1703USA005722.
Hands, arms and legs are itchy; Rash is mainly where touched/scratched - mostly arms, hands, and inside of thighs, its is on most of his legs, as well; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Hands, arms and legs are itchy) and RASH (Rash is mainly where touched/scratched - mostly arms, hands, and inside of thighs, its is on most of his legs, as well) in a 75-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011821A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included PARACETAMOL (TYLENOL), APIXABAN (ELIQUIS), ATORVASTATIN CALCIUM (LIPITOR), METOPROLOL TARTRATE (LOPRESSOR), VENLAFAXINE, PALIVIZUMAB and VITAMINS NOS (MULTIPLE VITAMIN) for an unknown indication.    On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Feb-2021, the patient experienced PRURITUS (Hands, arms and legs are itchy) and RASH (Rash is mainly where touched/scratched - mostly arms, hands, and inside of thighs, its is on most of his legs, as well). At the time of the report, PRURITUS (Hands, arms and legs are itchy) and RASH (Rash is mainly where touched/scratched - mostly arms, hands, and inside of thighs, its is on most of his legs, as well) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment medications includes Benadryl and some lotion.
Vision issues starting two days after 1st shot administered. Poor night vision including halos and bad starbursts, never had previous to shot. Increased sensitivity to light. Floaters increased. Headaches and migraines increased in frequency
hives, itching same side lower back/trunk area - took Dimetapp 20 ml - rash resolving
Itching; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A female patient received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for 1 day for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PRURITUS (non-serious), outcome "unknown", described as "Itching".  Additional information: The sister of a friends of reporter was going crazy with the itching as well. She was also experiencing this significant itching. Friend mentioned that her sister at times feels like shooting herself because the itching is so bad. That was a hyperbole for sure, but it gets bad.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
every bone in her body hurt; body aches all over; This spontaneous case was reported by a consumer and describes the occurrence of BONE PAIN (every bone in her body hurt) and MYALGIA (body aches all over) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 029K20A and 039K20A) for COVID-19 vaccination.     No Medical History information was reported.   On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced BONE PAIN (every bone in her body hurt) and MYALGIA (body aches all over). At the time of the report, BONE PAIN (every bone in her body hurt) and MYALGIA (body aches all over) outcome was unknown.            Concomitant and Treatment medications were not provided by reporter.   This case was linked to MOD-2021-021146 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 19-Apr-2021: Follow up received on 19-APR-2021 and it contains No new information
rash on left arm; injection site hard; injection site warm to touch; rash getting wider, up to 4 or 5 inches; fever; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (rash on left arm), INJECTION SITE MASS (injection site hard), INJECTION SITE WARMTH (injection site warm to touch), RASH (rash getting wider, up to 4 or 5 inches) and PYREXIA (fever) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE RASH (rash on left arm), INJECTION SITE MASS (injection site hard), INJECTION SITE WARMTH (injection site warm to touch), RASH (rash getting wider, up to 4 or 5 inches) and PYREXIA (fever). At the time of the report, VACCINATION SITE RASH (rash on left arm), INJECTION SITE MASS (injection site hard), INJECTION SITE WARMTH (injection site warm to touch), RASH (rash getting wider, up to 4 or 5 inches) and PYREXIA (fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were not reported. No treatment medications were not provided.
Soldier was to receive a Hepatitis B vaccine and received a Hepatitis A vaccine instead. Soldier had already completed his Hepatitis A series. Immunization record notes to Twinrix doses in the past and 3 Hep A doses.
After Receiving Heplisav-B Series , A Few Years Ago Titers Are Showing No Immunity; Initial Report Received on 19-Jul-2023   A physician reported to a sales representative that she, a female patient (race and ethnicity not provided), received the HEPLISAV-B (hepatitis B vaccine) series for hepatitis B immunization a few years ago and her titers showed no immunity.     No medical history, allergies, or concomitant medications at the time of vaccination were reported.    On unknown dates, the patient received the HEPLISAV-B series (Lot #s, expiration dates, NDC #s, route, and injection sites were not reported) when she started work at a hospital a "few years ago."     On an unknown date, she recently had a titer drawn and it showed no immunity to hepatitis B.    The patient declined to provide further information.   Company Comment: The company assessed the event as non-serious and not immunologically confirmed for vaccine failure. The dosing schedule and serological marker are not specified, and the time to titer was a "few years ago".; Sender's Comments: The company assessed the event as non-serious and not immunologically confirmed for vaccine failure. The dosing schedule and serological marker are not specified, and the time to titer was a "few years ago".
None. Parent had marked asthma on permission. Child received vaccine. Parent states child had a cold. Also states child did not have reaction to vaccine.
The day after I received the shot, I had an extremely high fever and a migraine. The migraine hasn't gone away. I have chronic swelling on both cheek bones. The swelling in conjunction with the headaches has made it difficult for me to focus and sometimes results in blurred vision. After I received the second shot in the series, I also had adverse effects, but those dissipated. I see my primary doctor regularly. He's referred me to an ENT and a neurologist- I have seen both and have had multiple appointments with the neurologist. Unfortunately, I am still suffering each day.
Tested positively for COVID; Tested positively for COVID; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 51 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 30Dec2021 13:30 (Batch/Lot number: unknown) at the age of 51 years as dose 3 (booster), single, intramuscular, administered in arm left, administration date 22Jul2021 16:45 (Batch/Lot number: unknown) as dose 2, single and intramuscular, administered in arm left, administration date 01Jul2021 11:00 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation.The patient's relevant medical history was not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient was not received any other vaccines within 4 weeks prior to the COVID vaccine.  The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 18Jan2022 12:30, outcome "recovering" and all described as "Tested positively for COVID". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (18Jan2022) positive, notes: Nasal Swab. Therapeutic measures were not taken as a result of vaccination failure, covid-19. The lot number for bnt162b2 was not provided and will be requested during follow up.
Redness, hot, hot flashes. L upper arm redness, swelling, pain. R ant chest with pain-hot flash, diaphoresis.
Pt experienced fever of 100.4, back pain, body aches, sore throat, dizziness and fatigue. Symptoms resolved, and improved fever by 11a, 8/22/18.
Just under 48 hours after the vaccine on 4/10/2021, I experienced a large swelling on either side of my neck, up and down the neck. I assume it was my lymph nodes. I felt as if someone was pushing my Adam's apple. Unpleasant and scary as I though it might get worse and I would choke. This lasted most of the day Saturday.  The same swelling and pressure in my throat occurred after the second Pfizer shot on 4/29/2021 (Lot Number: EW0153 ; 7/21/2021). This time it happened more quickly. Five hours after I received the shot. (Vaccine received at 11:30 am). The pressure in my throat lasted throughout the afternoon. I also felt burning and tingling at the site of the FIRST vaccine at this time.
Crying a lot, falling asleep between crying episodes.  Thigh of administration is red to the lower part of the knee anteriorly and thigh appears swollen.
Expired dose administered; This non-serious case was reported by a nurse via call center representative and described the occurrence of expired vaccine used in a 2-month-old female patient who received DTPa-HBV-IPV (Pediarix) (batch number 7P2Y3, expiry date 08-APR-2023) for prophylaxis.   On 05-MAY-2023, the patient received Pediarix (right thigh). On 05-MAY-2023, an unknown time after receiving Pediarix, the patient experienced expired vaccine used (Verbatim: Expired dose administered). The outcome of the expired vaccine used was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 05-MAY-2023 The reporter was enquired how to proceed, what to look for. The reporter reported a 2-month-old patient was inadvertently administered an expired Pediarix on the day of reporting in the Right thigh.  The reporter confirmed vaccine was administered in at facility.  The reporter did not consent to follow-up The patient received expired dose of Pediarix, which led to expired vaccine used.
Expired vaccine used; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .25 ml. On 26-Oct-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On 26-Oct-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The reporter informed that vaccine was removed from freezer on 13-OCT-2021 with a use by date of 12-NOV-2021 (30 days storage viability in the fridge) .Vial does not have an expiration date on it. However the Moderna Vail Expiration Date Checker states that this lot number has an expiration date of 24-OCT-2021 and administered  this lot number to patients on 25-OCT-2021 and 26-OCT-2021.  No concomitant medications were provided by the reporter. No treatment medications were provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 28-Oct-2021: Follow up received includes no new information.
Patient reports having headaches "on and off" since she recieved her vaccine. Patient stated that she was not sure if that was normal for her. Provider spoke with patient and advised patient to go to the near ER as soon as possible for further evaluation. Patient agreed.
Started having Covid-like symptoms, mainly cough and shortness of breath along with fatigue. Ran a low-grade fever for two days. Cough progressed and worsened and by the third day of symptoms I was bound to bed. Each time I moved, I couldn't breathe and coughed excessively.
HAD NIGHT SWEATS AND NIGHTMARES THE NIGHT OF VACCINE. FELT "FLU-LIKE" ON DAY 2.
Client c/o constant pain in left arm from last injections on July 27, 2017. Left arm red and slightly swollen. Warm to touch. Denies recent injury to left arm. Referred to Urgent Care. Mother reported she will take client to Urgent Care today. Advise to bring clearance to receive IPV and MMR from doctor. Translator utilized. Mother and client demonstrated understanding.
The patient arm had edema and fever. The site was red and warm to touch. Mom was instructed to give TYLENOL or MOTRIN for pain and edema. Also instructed to give BENADRYL for reaction. Instructed to call back if any other symptom or problems PRN.
Irregular menstrual cycle, started 2 days after injection. Still ongoing at time of reporting. Patient has an appointment with Gynecologist on May 3, 2021 and will discuss with physician.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 54-year-old male patient received BNT162b2 (BNT162B2), on 03Apr2021 as dose 1, single (Lot number: EW0150), in left arm, on 01May2021 as dose 2, single (Lot number: EW0173), in left arm, on 16Oct2021 as dose 3 (booster), single (Lot number: FF2590), in left arm and on 04Apr2022 as dose 4 (booster), single (Lot number: FJ9943) at the age of 54 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "HIV" (unspecified if ongoing). Concomitant medication(s) included: TIVICAY, start date: Jan2017; DESCOVY, start date: Jan2017; MONTELUKAST, start date: Jan2016. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive, notes: Treatment of COVID-19; (14May2022) Negative, notes: 2 negative at-home tests (Days 7 & 8); (15May2022) Negative, notes: 2 negative at-home tests (Days 7 & 8); (16May2022) Positive, notes: viral rebound occurred on Day 9 (after initiating treatment). Therapeutic measures were taken as a result of vaccination failure, covid-19.  Clinical course: No vaccine received and no other medication with in in 2weeks. Adverse event: After completing 5-day treatment course and symptoms (soar throat, fatigue, congestion, cough, headache and brain fog) surged back later the same day of viral rebound and were greater in severity than during initial infection. No known allergies, Other medical history: HIV  No follow-up attempts are possible. No further information is expected.